Inventor
Yasuharu Nishimura
Inventor
Kumamoto, JP
Overview
Patents· 22 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes23%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
C07KPeptides23%
C12NMicroorganisms or enzymes20%
C12YEnzymes5%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
A01KAnimal husbandry2%
PatentTitleYear
10,206,989CDCA1 epitope peptides for Th1 cells and vaccines containing the same201910,172,926KIF20A epitope peptides for TH1 cells and vaccines containing the same20199,770,498'IMP-3 epitope peptides for TH1 cells and vaccines containing the same'20179,687,538'CDCA1 epitope peptides for Th1 cells and vaccines containing the same'20179,644,010'LY6K epitope peptides for TH1 cells and vaccines containing the same'20179,561,265'KIF20A epitope peptides for TH1 cells and vaccines containing the same'20179,415,096'FOXM1 peptide and medicinal agent comprising the same'20169,404,925'Cancer antigen and use thereof'20169,132,176'RAB6KIFL/KIF20A epitope peptide and vaccines containing the same'20159,120,842'SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same'20159,073,968'FOXM1 peptide and medicinal agent comprising the same'20158,883,966'RAB6KIFL/KIF20A epitope peptide and vaccines containing the same'20148,598,125'CDCA1 peptide and pharmaceutical agent comprising the same'20138,586,547'CDC45L peptides and vaccines including the same'20138,569,244'FOXM1 peptide and medicinal agent comprising the same'20138,535,942'Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same'20138,470,968'SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same'20138,455,444'CDH3 peptide and medicinal agent comprising the same'20138,053,556'Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same'20118,053,557'SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same'20118,017,345'Diagnostic kit for malignant melanoma'20117,803,533'Diagnostic agent for malignant melanoma'2010Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2010–2019Based in Kumamoto, JP· patent location history
2011–2019Patents assigned to ONCOTHERAPY SCIENCE INC (15)· patent assignee history
2011–2015Patents assigned to ONCO THERAPY SCIENCE INC (4)· patent assignee history
2013–2016Patents assigned to NISHIMURA YASUHARU (8)· patent assignee history
2013–2014Patents assigned to NAKAMURA YUSUKE (5)· patent assignee history
2013–2014Patents assigned to TSUNODA TAKUYA (5)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ONCOTHERAPY SCIENCE INC | 15 | 2011–2019 |
| NISHIMURA YASUHARUself | 8 | 2013–2016 |
| NAKAMURA YUSUKE | 5 | 2013–2014 |
| TSUNODA TAKUYA | 5 | 2013–2014 |
| ONCO THERAPY SCIENCE INC | 4 | 2011–2015 |
Locations
| Location | Patents | Span |
|---|---|---|
| Kumamoto, JP | 22 | 2010–2019 |